The U.S. Supreme Court has denied certiorari in Novartis v. Fussman.  Novartis’s petition asked the court to decide whether federal law preempts punitive damages claims against drug manufacturers who have satisfied FDA approval and labeling requirements. The court requested a response to the petition, but ultimately decided not to take up the case.

The court’s order list is here.  Law 360 has coverage here (subscription required).

Related posts:

Novartis cert. petition distributed for Sept. 30 conference

Cert. petition asks Supreme Court to address preemption of punitive damages claims against drug makers (Novartis v. Fussman)